bioRxivImmunology
High-Grade Serous Ovarian Tumor Cells Modulate NK Cell Function to Create an Immune-Tolerant Microenvironment
V. D. Gonzalez, Y.-W. Huang, S.-Y. Chen, A. Delgado-Gonzalez, K. Donoso, A. Gentles, K. Sachs, E. Porpiglia, W. Fantl
Abstract
Tubo-ovarian high-grade serous cancer (HGSC) is unresponsive to immune checkpoint blockade despite significant frequencies of exhausted T cells. Here we applied mass cytometry to uncover decidual-like (dl)-NK cell subpopulations (CD56+CD9+CXCR3+KIR+CD3-CD16-) in chemo-naive HGSC tumors that correlated with both tumor and transitioning epithelial-mesenchymal cell abundance. We showed different combinatorial expression patterns of ligands for activating and inhibitory NK receptors within the three HGSC tumor cell compartments; epithelial (E), transitioning epithelial-mesenchymal (EV) and mesenchymal (vimentin-expressing cells, V) with a more inhibitory ligand phenotype in V cells. When co-cultured with HGSC cell lines the NK-92 cell line acquired CD9 from tumor cells by trogocytosis with a resultant reduction in both anti-tumor cytokine production and cytotoxicity. Critically, a CD9 blocking antibody restored the killing activity of CD9+-NK-92 cells. These findings identify previously unrecognized mechanisms of immune suppression in HGSC. Furthermore, since CD9 is widely expressed in HGSC tumors it represents an important new therapeutic target with immediate relevance for NK immunotherapy.
- organism: human
- assay: flow cytometry
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- research focus: cell type annotation
- approach: experimental assay
- approach: wet-lab / biochemical assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Dual G9A and EZH2 inhibition stimulates an anti-tumour immune response in ovarian high-grade serous carcinoma
P. Spiliopoulou, S. Spear, … I. McNeish·bioRxiv·May 9, 2021
- Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer
Zhen Zeng, Anastasia Gandini, … Brian G. Gabrielli·British Journal of CancerPeer-reviewed·Apr 7, 2026
- Single-cell analysis reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of ovarian cancer
L. Zhang, S. Cascio, … H. U. Osmanbeyoglu·bioRxiv·Jun 7, 2023
- NGFR-driven suppression of antigen presentation limits CD8+ T cell immunity and response to checkpoint blockade
Juan García-Agulló, Vanesa Santos, … Héctor Peinado·bioRxiv·Aug 25, 2026
- A TEMPORAL MODEL OF TUMOR-IMMUNE DYNAMICS IN HIGH GRADE SEROUS OVARIAN CANCER
Donagh Egan, Kate Glennon, … Donal J. Brennan·npj Precision OncologyPeer-reviewed·Jun 16, 2025
- High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils
Alexander Emmanuelli, Camilla Salvagno, … Juan R. Cubillos‐Ruiz·OncoImmunologyPeer-reviewed·Oct 2, 2024